Impact of the use of immunoglobulin palivizumab in the State of São Paulo: a cohort study

Gonçalves, Ivana Regina; Duarte, Marli Teresinha Cassamassimo; Nunes, Helio Rubens de Carvalho; Alencar, Rubia de Aguiar; Parada, Cristina Maria Garcia de Lima.
Rev. latinoam. enferm. (Online) ; 25: e2928, 2017. tab, graf
Artigo em Inglês | LILACS, BDENF | ID: biblio-961088

Documentos relacionados

  1. Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children.
  2. Up-to-date role of biologics in the management of respiratory syncytial virus.
  3. Study protocol: a multicenter, uncontrolled, open-label study of palivizumab in neonates, infants, and preschool children at high risk of severe respiratory syncytial virus infection.
  4. Expansion of the 1st WHO international standard for antiserum to respiratory syncytial virus to include neutralisation titres against RSV subtype B: An international collaborative study.
  5. Target Trial Emulation and Bias Through Missing Eligibility Data: An Application to a Study of Palivizumab for the Prevention of Hospitalization Due to Infant Respiratory Illness.
  6. A Systematic Review of European Clinical Practice Guidelines for Respiratory Syncytial Virus Prophylaxis.
  7. Effectiveness of Palivizumab Against Respiratory Syncytial Virus Hospitalization Among Preterm Infants in a Setting With Year-Round Circulation.
  8. Human respiratory syncytial virus: pathogenesis, immune responses, and current vaccine approaches.
  9. Intravenous palivizumab in respiratory syncytial virus infection after hematopoietic stem cell transplant in children.
  10. Use of Palivizumab in Germany - Report from the German Synagis™ Registry 2009 - 2016.